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The antigenic structure of tumor cells may be critical in determining their growth 
characteristics and metastatic properties. Moreover, the immunologic response to the 
tumor can act as a powerful selective force influencing the final nature of these prop- 
erties. The antigenic alterations which take place on the surface of normal cells when 
they are transformed may be qualitative, as exemplified by the gain of tumor-specific 
transplantation antigen(s) (TSTA)  1 or the complete loss of a normal antigen, or they 
may be quantitative, as in the modulation of normal histocompatibility antigens. The 
quantity of H-2 isoantigen on the surface of different normal and tumor cells of the 
mouse has been shown to vary depending on the age of the animal (1-3), type of tissue 
or tumor (1, 4--6), and the immune state of the host (7-9). Recent serological studies 
(10,  11), the fluorescent antibody study of Cerottini and Brunner (12),  and the im- 
munoferritin  study of Aoki et al. (13) all suggest that the antigenic specificities within 
the H-2 system are located in "patches" on the cell surface.  Klein (14) proposed that 
the total amount of surface H-2 antigens may change but that a minimum concentra- 
tion is necessary for cell viability. Within these limits, alterations in individual H-2 
antigens in carcinogenesis could carry important genetic implications depending on 
whether there is a loss or decrease of one specificity on all tumors, a completely random 
change in the various specificities,  or a coordinated alteration of all specificities. 
The relationship between the TSTA and normal H-2 antigens is of interest because 
of the possible role that these surface components may play in cellular recognition. 
A reciprocal relationship between the thymus-leukemia (TL) and normal transplanta- 
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tion antigens has been demonstrated by Boyse, Stockert, and Old (15) on leukemia cells 
where the new phenotypic  expression  of the TL antigen was  associated with  a  con- 
current loss of H-2 antigens. Fenyo et al. (9) utilized immunized mice to select Moloney 
lymphoma  cells with  a  decrease  in  Moloney-specific surface  antigen.  They  also  re- 
ported preliminary  studies  demonstrating  a  reciprocal increase in H-2  antigens. 
Most  of  the  quantitative  studies  on  H-2  antigens  on  the  surface  of  ceils 
have  been  carried  out  using  multispecific  isoantisera  against  several  alloanti- 
genic specificities. Therefore,  little is known  about  the variation  of individual 
antigens  within  the  H-2  system  or  about  their  relationship  to  tumor-specific 
antigens. The present study was undertaken  to compare the antigenic make-up 
of  several methylcholanthrene  (MCA)-induced  tumors  in mice.  The  amounts 
of normal H-2  antigens  were determined  by quantitative  absorption  of mono- 
specific antisera  and by the sensitivity of the tumors to the cytotoxic action of 
antibody  and  C r.  The  immunogenicity  of  the  tumor-specific  antigens  were 
estimated  on  the  same  tumors  by  a  standardized  in  vivo immunization  and 
challenge.  A  characteristic  reciprocal  relationship  was  found  to  exist between 
the  normal  H-2  antigen  concentration  and  tumor-specific  immunogenicity  in 
the series studied.  Moreover, the pattern of cellular antigenicity correlated well 
with a behavioral property of the  individual tumors,  namely  their capacity  for 
early metastasis  to the lung. 
Materials and Methods 
Animals.--C3H/HeJ inbred female mice, 6-12 wk old, were used in all of the studies. This 
strain carries the H-2 k allele with the following alloantigenic specificities: 1, 3,  5, 8,  11, 25, 
32  (16). Inbred DBA/2 and A.SW mice were used for immunization with C3H/HeJ cells. All 
mice were purchased from the Jackson Laboratories, Bar Harbor, Maine. They were housed in 
air conditioned animal rooms, fed Purina lab chow, and watered ad libitum. 
[rradiatlon.--The mice were irradiated with 350 rads whole body irradiation to the midline 
in a  rotating plastic holder with a  General Electric Maximor 220  machine.  The radiation 
characteristics were 220 kvp, 15 ma, 60 cm tube to surface distance, with a  1 mm A1 and a 
0.25 Cu filter delivered at a dose rate of 70.6  fads per min. with full wood  backscatter  for 
4.25rain. 2 
Tumors.--Five different MCA-induced sarcomas were used. These were induced with 0.5 
mg MCA dissolved in 0.1 ml trioctanoin injected intramuscularly in the hind legs of C3H mice 
(17).  The tumors were numbered MC-1, MC-2, MC-3, MC-4, and MC-5, banked in liquid 
N2, and transplanted  in isogeneic mice. The earliest tumor used was transplanted  from the 
original host 10 wk, and the latest 18 wk, after injection of MCA. The tumors were used be- 
tween the 12th and 22nd in vivo transfer. 
Preparation. of Tumor Cells  for Study.--Using sterile technique, tumors were removed from 
the mouse, minced, and treated with 0.5% trypsin in Eagle's minimal essential medium (MEM) 
tissue culture media for 1 hr at 25°C.The tumor cells were then  cultured  in  plastic  Petri 
plates in F-10 media supplemented with 20% fetal calf serum, 100 units penicillin, and 100 mg 
2 The irradiation was carried  out by Dr. Richard Kenyon in the Department  of Radio- 
therapy, University of Minnesota Hospital. GERALD R.  I-IAYWOOD AND  CHARLES  F.  McKHANN 
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Production  of Monospecific  H-2  Antisera  against  Alloantigens  on  C3H  Cells 
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Alloantigenic  specificity  Recipient/donors 
H-2.1, 19 
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(B10  X  LP.RIII)/B10.BR 
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FIG. 1.  Titration of monospecific  H-2.1, 3, 5, 8, 11, 23, and 32 antisera against C3H lymph 
node cells. 
streptomycin/milliliter in a humidified, gassed  (5% CO2,95% air) 37°C incubator. After 24 
hr of culture the plates were washed with media to remove dead cells and the tumor ceils were 
removed by pipetting them off with 4  ml of Versene-trypsin,  (0.2~/c ethylenediaminetetra- 
acetic acid  [EDTA], 0.02% trypsin, 0.04% KC1, 0.8% NaC1, and 0.005% phenol red, pH 7.4). 
Within 4 rain the cells were placed in an equal volume of MEI~ containing 20% fetal calf 
serum. The cells were then washed three times in  199 tissue culture media containing 0.1% 1174  ANTIGENIC  SPEC1-FICITIES ON  MURINE  SARCOMA CELLS 
bovine serum albumin (199 BSA), by centrifuging at 650 g for 6 min in a  refrigerated cen- 
trifuge. The tumor cells were resuspended in 199 BSA. 
Antisera.--The "monospecific" antisera used in this study were produced by Dr.  George 
Snell at  the Jackson Laboratories (National Institutes of Health contract PH 43-66-483). 
Table I gives the donor and recipient combinations used in the production of these antisera. 
It should be noted that recipients were F~ hybrids in which one of the parents was from a 
strain congenic with the donor. This assures that, within the genetic limits of the congenic 
resistant animals, no non-H-2 antibodies are present in the serum. As can be seen in Table I 
the sera may contain antibodies against more than one specificity. However, they are mono- 
specific for only one antigen represented on the C3H cells. Anti-H-2.3, H-2.11,  and H-2.23  did 
show cross-reactivity with one of the other C3H specificities  as detected by agglutination or 
cytotoxicity (M. Cherry. Jackson  Laboratories. Personal communication.).  H-2.25 was excluded 
from this study because the available antisera was not cytotoxic. Individual monospecific  anti- 
sera was titrated with 51Cr-labeled lymph node cells (LNC). Fig. 1 shows the titration curves 
of the antisera. The per cent of 51Cr released was directly proportional to the killing  of cells 
as measured by vital dye exclusion. The dilution of antisera which gave 50% release of ~lCr 
was defined as the titer. 
Multispecific antisera were produced by immunizing mice with spleen cells. Recipient mice 
were given donor spleen cells subcutaneously once a week for 6 wk. 10 days after the last in- 
jection the recipients were bled from the retroorbital plexus. All sera were stored in 0.25 ml 
volumes at -- 70°C. 
Complement.--Sera from rabbits were screened for high complement (C') activity and low 
natural cytotoxicity. Selected sera were absorbed once for 5 min at  --2°C with minced liver 
and spleen tissue. Mter absorption the C' was titrated with excess antibody and stored in 
0.5 ml samples at --70°C. 
Cytotoxic Test.--The cytotoxic test, measuring release of 5tCr from labeled lymph node ceils, 
was adapted directly from the technique of Wigzell  (18). LNC,  teased from the inguinal, 
axillary, popliteal, and mesenteric lymph nodes, in medium 199 were labeled with 200/zl of 
Na251CrO4  (1.1 mCi/ml from the Radiochemieal Centre, Amersham, England) for 45  min at 
37°C. After washing, the labeled cells were counted and tested for viability with trypan blue. 
Only preparations with greater than 90% viable cells were used. The cells were diluted to 
500,000/50  #1 in 199 BSA. Twofold serial dilutions of antiserum were prepared in 199 BSA with 
50/zl of each dilution per tube. 50 #1 of labeled cells were then added to each tube, mixed, and 
incubated for 10 rain at 37°C.  50 #1 of C r was added to each tube and the tubes incubated 
for 1 hr at 37°C with frequent mixing. Mter incubation 1.5 ml of phosphate-buffered  saline was 
added, the tubes mixed and centrifuged. 1 ml of the supernate was carefully drawn off and 
counted in a  Tracerlab gamma-radiation counter  (Tracerlab Div., LFE Electronics, Rich- 
mond, Calif.). 
The amount of atCR in 1 ml of fully labeled cells was determined as a high control. Controls 
to determine the background, caused by antibody or C' alone, were also included. C r con- 
sistently gave the highest background and was used as the background control in the calcula- 
tions. The per cent of 51Cr released was calculated by tile formula: 
cpm from sample-cpm from C' control 
X  100 
cpm from high control-cpm from C' control 
Quantitative Absorptlon.--The  quantitative absorption technique was adapted from Boyse 
et al.  (19). Tumor cells were counted and adjusted to the appropriate numbers needed to 
absorb the antisera as determined by preliminary studies. Only preparations of single cells in 
suspension  were used. Tumor cells were serially diluted in 1 ml of 199 BSA, centrifuged, and the 
media carefully aspirated off. 170 btl of antiserum was added and the cells suspended by shak- GERALD  R.  HAYWOOD AND  CHARLES  F.  McKHANN  1175 
ing. The antiserum was absorbed for 30 min at 37°C followed by 30 min at 4°C, with frequent 
shaking. Control antisera were incubated at the same time without tumor cells.  The  tubes 
were centrifuged at 700 g and the absorbed antiserum carefully removed and stored at -- 70°C 
until all of the absorptions were complete. This provided enough absorbed antisera to allow 
three complete assays. All calculations were done with reference to 50 #1 of antiserum, as used 
in the assay, i.e. when 170/zl of antiserum was used 3.4 times as many tumor cells were needed 
as would have been used to absorb 50/zl. 
The size of the cells from these tumors varied slightly. Since the following experiments 
were based upon a comparison of the surface antigens, the number of cells used was corrected 
to give an equivalent surface area. Table II presents the data and calculation used in determin- 
ing the correction factor. The surface area of the cell was calculated by the formula A  =  7rD 2, 
assuming that the cells in suspension are spherical. 
Calculation of Lethal Dose.--The method of Reed and Munch (20) as discussed by Davis et 
al.  (21) was used to calculate a TPD-50, the number of cells needed to kill 50% of the mice 
receiving tumors. This method takes advantage of using small numbers of animals in a  group. 
This was accomplished by assuming that if one animal dies at low dose it would have died at 
TABLE  II 
Average Surface Areas of Cdls of Different MCA  Tumors 
Tumor  Number of  Mean cell  Mean surface  Correction 
cells sized  diameter  +  SE  area  factor 
(t*)  (~*) 
MC4  30  18.15  0.43  1034  1.00 
MC-1  30  17.56  1.27  968  1.07 
MC-2  30  16.92  0.58  899  1.15 
MC-5  30  16.67  0.60  872  1.19 
MC-3  30  14.92  0.46  698  1.48 
the next higher dose and accumulating the values of the total number of animals that died or 
survived. The 50% point is then extrapolated between the two doses above and below the 500/0 
point. 
RESULTS 
Quantitative  Absorption  of Morwspecific  Antisera  with  Different  MCA  Tu- 
mors.--The  relative amount of each individual H-2  aUoantigen was determined 
on  five  different  MCA-induced  tumors  by  quantitative  absorption  of  mono- 
specific  antisera.  Each  antiserum  was  assayed  for  the  amount  of  antibody 
remaining after quantitative  absorption with the different tumors. The amount 
of  antibody  in  the  unabsorbed  control,  as  measured  in  counts  per  minute 
released from the labeled LNC,  was taken as 100%.  The per cent of antibody 
remaining after  absorption  by various numbers  of  tumor  cells was  calculated 
from  the  counts  per  minute  released  in  the  cytotoxic  assay  of  this  sample 
divided by the control, times 100. The number  of cells used for the absorptions 
and plotted on the graph was corrected to give an equivalent surface area. The 
quantitative  absorption  of  anti-H-2.11  with  the different  tumors  is  shown in 
Fig.  2.  From  this graph  the number  of  cells necessary  to  absorb  50%  of  the 1176  ANTIGENIC  SPECYFICITIES ON  MURINE SARCOMA CELLS 
antibody was  determined. It  can be  seen that  tumor  MC-1  required about 
eight times more cells to absorb the sane amount of antibody as did MC-5. 
The  number of  cells necessary to  absorb  50%  of  each  monospecific anti- 
serum was determined for each of the tumors, as shown in Table III. In order 
to make a  relative comparison of the amount of each  antigen on the surface 
of the tumors, tumor MC-3 was  arbitrarily chosen as a standard. The average 
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Fro. 2.  Quantitative absorption of anti-H-2.11 sere with each of the five different MCA 
sarcomas, and tested for residual cytotoxicity. The number of cells necessary to absorb 50% of 
the antibody was determined from the graph. 
of the duplicates in Table III was calculated and the number of  cells of MC-3 
necessary to  absorb  50%  of  each  monospecific alloantiserum was  defined as 
unity. The number of cells needed to absorb  a  given amount of antibody was 
compared to the number of cells of MC-3 needed to absorb the same amount 
of antibody. This ratio expresses the quantity of antigen in terms of its capacity 
to absorb antibody relative to tumor MC-3. Table IV gives the relative amount 
of  each  antigen on the  individual tumors compared with  MC-3.  These data 
are summarized in a bar graph in Fig. 3 from which it can be seen that tumor 
MC-1 has a relatively large amount of all antigens and MC-5 has the smallest GERALD  R.  HAYWOOD  AND  CHARLES  F.  McKHANN  1177 
amount of all antigens. When the ratios of all of the antigens on an individual 
tumor are grouped together and compared, tumor MC-1  has 5.75  times more 
absorbing ability  than  MC-5.  The  other tumors  fall  in  between in  the  order 
TABLE  III 




1  3  5  8  11  23  32 
MC-1  1.1  1.6  0.~  1.9  0.74  0.94  2.5 
0.7  0.73  0.62  2.3  0.45  0.9  2.5 
MC-2  1.5  2.1  1.4  2.3  1.26  2.1  6.4 
1.3  1.15  1.1  2.6  0.77  2.0  6.0 
MC-3  3.6  4.9  3.2  5.8  2.8  4.4  8.8 
1.7  2.8  2.2  6.8  2.8  4.4  8.1 
MC4  4.3  5.7  1.6  7.6  3.1  5.4  9.5 
2.7  3.1  0.92  5.4  2.2  4.5  10.9 
MC-5  7.0  8.1  6.4  6.0  6.4  4.4  7.8 
--  --  3.8  9.4  5.4  6.1  7.4 
* Duplicate assays of absorption of all of the 7 mono-specific  sera by each of the 5 tumors. 
TABLE  IV 
Absorbing Capacity of Different MCA Sarcomas Rdative to MC-3* 
Alloantigenic specificity 
Tumor 
1  3  5  8  11  23  32 
Average of all 
antigen 4- SE 
on  each tumor 
MC-1  2.85  3.45  4.28  3.01  5.0  4.62  3.16  3.77  0.32 
MC-2  1.85  2.38  2.15  2.57  2.75  2.08  1.37  2.16  0.18 
MC-3  1.0  1.0  1.0  1.0  1.0  1.0  1.0  1.0  -- 
MC-4  0.75  0.88  2.20  1.01  1.09  0.86  0.84  1.09  0.19 
MC-5  0.51  0.61  0.54  0.83  0.48  0.84  1.11  0.76  0.11 
* The average of the number of cells necessary to absorb 50% of each antibody was de- 
termined from Table III. Tumor MC-3 was chosen as a standard and the ratio determined for 
the number of cells of each tumor required to absorb 50% of the antibody as compared with 
MC-3. 
MC-1  >  MC-2  >  MC-4 >  MC-3  >  MC-5. There was no gain or loss of any 
single specificity nor was there a  random gain or loss of many  different anti- 
gens.  Instead,  there  was  a  quite  uniform alteration  in  all  of  the  antigens on 
an individual tumor. 1178  ANTIGENIC  SPECIEICITIES  ON  MURINE  SARCOMA  CELLS 
Sensitivity  o.f MCA  Tumors to Cytotoxicity of Antibody  and Complement.--A 
direct cytotoxic test was carried out on each of the five MCA-induced tumors 
using a  multispecific anti-C3H antiserum. Tumor cell  suspensions were  pre- 
pared as for absorption and labeled with 51Cr in the same way as LNC. 500,000 
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FIG. 3.  Absorbing capacity of individual H-2 alloantigens on different MCA sarcomas rela- 
tive to MC-3. No specificities are missing from any tumor and each tumor had its own co- 
ordinated level of antigenicity with no aberrant high or low levels of any one specificity. 
From Fig. 4 it can be seen that there was a  significant difference in the killing 
of  different  tumors  with  the  same  antibody and  C'.  The  concentration of 
antigen on the  surface  of the  tumor cells,  as reflected by their sensitivity to 
antibody and  C',  is  again in the  same  order:  MC-1  >  MC-2  >  MC-3  > 
MC-4 >  MC-5. 
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onstrated by optimal immunization of animals and then challenge with different 
doses of viable tumor cells.  In these studies the immunogenicity of the tumors 
was evaluated under more standard conditions by setting up a constant single 
immunization  and  challenge  schedule  for all  of the  tumors.  Large groups of 
mice were immunized by giving 106 viable tumor cells intramuscularly in the 
leg.  7  days after the injection  the legs with  tumors were amputated.  5  days 
later the mice were divided into groups of five and challenged with serial doses of 
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FIG.4. Direct cytotoxic effect of multispecific  H-2 antisera (DBA/2 anti-C3H) against dif- 
ferent MCA-indueed tumors and normal lymph node cells. 
tumor cells by subcutaneous injection on the back.  All immunized mice were 
challenged with the same tumor with which they were immunized.  Ceils from 
the  same  tumor  suspension  were  used  to  challenge  groups  of  unimmunized 
control mice. The number of mice developing tumors over the number of mice 
challenged is presented in Table V. The 50 % tumor-producing dose (TPD-50) 
was computed to give a quantitative comparison of the immunogenicity of the 
different tumors.  Table V  also shows the TPD-50 for each of the  tumors in 
control and immunized mice. This experiment demonstrated no immunogenicity 
for tumors MC-1, MC-2, or MC-3. However, there was a 10-fold increase in the 
number of tumor cells needed to produce tumors in 50 %  of the immune mice 1180  ANTIGENIC  SPECIFICITIES  ON  MURINE  SARCOMA  CELLS 
with tumors MC-4 and MC-5. The TPD-50 in the controls also gives a measure 
of immunogenicity. The TPD-50,  shown in the control column of Table V  for 
tumors MC-3,  MC-4,  and MC-5, was  10 times greater than for tumors MC-1 
and MC-2. From these data it was determined that the immunogenicity of the 
five tumors is in the order: MC-5  =  MC-4  >  MC-3  >  MC-2  =  MC-1. 
Metastasis.--The  role of the  antigenic structure  of tumor  cells on  the bio- 
logical properties of the tumor is not well defined. If the autochthonous animal 
has an immune response to the tumor,  the strength of the tumor-specific anti- 
gen could play an important role in the ability of a  tumor to metastasize. 
An  experiment  was  designed to  test  the  ability of  the  various  tumors  to 
metastasize to the lung. Groups of four anfinals were given 106 viable tumor cells 
TABLE V 
Incidence of Tumor Growth in Immunized Mice* 
Tumor 
Number of cells used for challenge 
10~  10  4  10  3  10  2 
Control  Immune  Control  Immune  Control  Immune  Control  Immune 
TPD-50 
Control  Immune 
MC-1  5/5  4/5  4/5  5/5  3/5  4/5  2/5  0/5  120  120 
MC-2  5/5  2/4  5/5  4/4  4/5  4/5  1/5  0/5  120  110 
MC-3  3/5  4/5  4/5  4/5  4/5  3/5  0/5  1/5  1000  1000 
MC4  5/5  2/5  3/5  1/5  2/5  1/5  2/5  0/5  1280  11450 
MC-5  2/3  2/4  3/4  2/5  1/5  0/5  1/5  0/5  1290  12700 
* Mice were immunized with 10  s tumor cells 12 days before challenge with various doses of 
cells from the same tumor. Tumors growing from the immunization were removed  by am- 
putation 5 days before challenge. The table gives the number of mice developing tumors/the 
number of mice challenged. Last column indicates number of cells of each tumor required to 
kill 50%  of normal or immunized  mice,  used  to establish sequence  of tumor-specific  im- 
munogenicity. 
subcutaneously.  14 days later the mice were  sacrificed and the lungs removed. 
The  lungs  from  each  animal  were  minced  and  injected  subcutaneously  into 
C3H mice previously given 350 R  of whole body X-irradiation. For 3 months the 
irradiated mice were  watched for the development  of tumors.  The  results in 
Table VI  show  that  tumors  MC-1  and  MC-2  had metastasized in  all of the 
animals by 2 wk. These were the same tumors with the greatest amount of H-2 
antigen and the lowest tumor-specific immunogenicity. Tumors MC-3,  MC-4, 
and MC-5 showed only a  slight degree of metastasis at this time. If the tumors 
were allowed to grow for 3  or 4  wk they all metastasized to the lung but also 
killed the animals by progressive growth of the original tumor. The results of 
these experiments are summarized in Table VII. 
DISCUSSION 
The variation among normal and tmnor-specific transplantation antigens on 
the  surface  of  cells  transformed  by  carcinogens  suggests  that  they  play  a GERALD  R.  HAYWOOD  AND  CHARLES  :F.  McKItANN  1181 
critical role in the tumor-host relationship. Quantitative absorption and sensi- 
tivity to cytotoxicity of antibody can both be used to demonstrate H-2  anti- 
genic  differences  between  tumors.  In  the  present  experiment  quantitative 
absorption  of monospecific H-2  antisera  was  used  to  study  the  variation  of 
individual H-2  antigenic determinants on five MCA-induced tumors. No  pat- 
tern of individual antigenic gain or loss could be detected. Such a picture would 
have been predicted if the TSTA had replaced one of the H-2 determinants or if 
TABLE VI 
Incidence  of  Pulmonary  Metastasis in  Mice  with  Different MCA  Tumors* 
Tumor 
Day of lung transfer 
14  21  31 
Number lung metastases/mouse 
MC-1  4/4  4/4  -- 
MC-2  4/4  3/3  4/4 
MC-3  2/4  4/4  3/3 
MC-4  1/4  1/2  1/1 
MC-5  0/4  2/2  2/2 
* Mice were given 106 viable tumor cells 14, 21, and 31 days before the lungs were trans- 
ferred to immunologically suppressed  animals.  All groups had lungs injected into four mice 
and the table gives the number of mice developing tumors per number of mice receiving lungs. 
TABLE VII 
Summary of Studies of tt-2 Antigenicity, Tumor-Speclfic  Immunogenicity, and Early Puhnonary 
Metastasis of Five MCA Sarcomas 
H-2  Tumor antigen 
Absorption  Cytotoxicity  LD  ~0  Metastasis 
MC-1  +++++  +++++  +  ++++ 
MC-2  ++++  ++++  +  ++++ 
MC-3  ++  ++  ++  ++ 
MC-4  ++  +  +++  + 
MC-5  +  +  +++  + 
it had altered all but one. The results showed that all of the antigens on a given 
tumor were altered to the same relative degree. Whether or not there was an 
actual increase or decrease in the concentration of antigen on the surface of the 
cells would require comparison with the normal tissue from which the tumors 
derived. Assuming that the MCA fibrosarcomas were derived from fibroblasts, 
quantitative absorption studies were carried out on 18-day old mouse embryo 
fibroblasts cultured in vitro for 24 hr. There was so little H-2 antigen on these 
fibroblasts that the comparison was not meaningful. Quantitative studies with 1182  ANTIGENIC  SPECIFICITIES  ON  MLrRINE  SARCOMA  CELLS 
adult fibroblasts or embryo fibroblasts maintained longer in culture were not 
done. 
Sensitivity of the five tumors to the direct cytotoxic action of a multispecific 
anti-H-2 serum and C' provided an alternate method for comparing the relative 
total antigenicity of the tumors. The cytotoxic sensitivity of the various tumors 
correlated well with the average of the amount of all antigens as determined by 
quantitative absorption. From these results it was possible to put the tumors 
in an arbitrary sequence with regard to their H-2 antigenicity (MC-1  through 
MC-5). 
A  coordinated change  in  all determinants  from a  given allele is consistent 
with the observations of Klein and Klein (22)  and Hellstrom (23)  on selected 
tumor variants in  which  a  tumor from a  F1  hybrid may lose  all  of the H-2 
antigenic expression of one or the other parent but not from both. The regions 
and specificities, with respect to the H-2  k allele, are shown in Fig. 5. Region K 
is separated from E  by a locus producing a serum protein and cross-overs have 
been recognized.  In the  studies  of Old  et ah  (24)  on  the modulation  of H-2 
(3)  (5)  (II) 
D  C  V  E  ss  K 
I  I  I  I  It  I 
FIC. 5.  A schematic map of the H-2 region of the IXth linkage group of the mouse showing 
the determinants used in this study (16). 
antigens by TL antibody there was a  quantitative  alteration  of the antigens 
representing the C region but not the K  region. In the current study regions C, 
E, and K  are expressed by antigens 3,  5, and 11. The finding of a coordinated 
alteration of the antigens for C and K in the present study and a noncoordinated 
change in the studies of Old et ah suggest that there are at least two levels of 
control of the expression of surface H-2 antigens. 
To compare the tumor-specific immunogenicity of the same tumors, a stand- 
ardized immunization challenge was carried out in isogeneic mice.  Comparison 
of the TPD-50 in nonimmunized and immunized  mice suggested that tumors 
MC-1,  MC-2,  and MC-3 had  no immunogenicity. Tumors MC-4  and  MC-5 
demonstrated a 10-fold increase of the TPD-50 in the immune mice, suggesting 
a  greater antigenicity. Tumors  MC-3, MC-4, and MC-5 had a  10-fold greater 
TPD-50 in nonimmune mice compared with  MC-1  and MC-2.  Therefore the 
order of the tumors with respect to their tumor-specific  immunogenicity was 
MC-5, MC-4, MC-3, MC-2,  MC-1. The sequence is exactly the inverse of that 
related to H-2 antigenicity. 
The concept that the surface of the cell is "organized as a mosaic" (25)  was 
further advanced in a discussion by Boyse and Old (26)  in which they viewed 
the cell surface as a  precise grid,  individuality being conferred by unique  ar- FIG. 6.  Models of cell surface showing possible relationship between H-2 and tumor-specific 
antigeic sites.  (1)  Surface of normal cell,  showing different H-2 specificities associated  with 
each other in clusters.  (2 and 3)  Tumor-specific antigens remote from and  replacing entire 
clusters of H-2  antigens.  (4 and 5)  Tumor-specific antigens intimately associated with and 
replacing H-2 antigens inside individual clusters. Each of these models would explain reciprocal 
relationships between H-2 and tumor-specific antigenic systems. 
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rangements of relatively few gene products.  The present studies indicate  an 
inverse  relationship  between  the  TSTA  and  the  normal  histocompatability 
antigens. This is consistent with the studies of Old et al. (24)  and Fenyo et al. 
(9) demonstrating an alteration in the quantity of H-2 antigens by the modula- 
tion of either TL on leukemia cells or the TSTA on Moloney lymphoma cells. 
If the H-2 antigens are present on the cell surface in "patches," as indicated by 
recent  studies,  two  different  general  configurations  are  suggested.  (Fig.  6) 
(a)  Tumor-specific sites may be independent of the normal  antigens;  with  a 
large amount of TSTA the normal patches could be crowded out, producing 
fewer patches.  (Fig. 6, sections 2 and 3)  (b) The alternative would be for the 
TSTA to be intimately related to the H-2 patches (Fig. 6, sections 4 and 5) and 
in  this  way be  expressed at  the  expense  of normal  antigens.  If  subsequent 
studies prove this latter model to be correct, two further alternatives will be 
FIC. 7. Mechanisms by which primary deletions of normal antigens from clusters could 
result in new, tumor-specific  specificities. 
open for consideration. The tumor-specific antigen may be entirely new, having 
no relationship whatsoever to existing normal antigens on the cell, as depicted 
in Fig.  6.  Alternatively, primary deletion of H-2  antigenic specificities from 
their normal position within the cluster may result in rearrangements and new 
relationships between existing specificities that result in entirely new, tumor- 
specific antigens, as shown in Fig. 7 and as suggested by Boyse and Old (26). 
MCA-induced sarcomas metastasize to the lungs under appropriate experi- 
mental conditions. The primary tumor must remain in the host long enough to 
allow the circulating tumor cells to establish in the lungs, yet be removed soon 
enough  that  the  primary tumor  does  not  kill  the  animal  (27).  The studies 
presented here show that the ability of MCA-induced sarcomas to metastasize 
to the lung correlates with the antigenic make-up of the tumor. Tumors with 
relatively large  amounts  of  normal  H-2  antigen  and  low  TSTA  antigenic 
strength  (MC-1  and MC-2)  established viable tumor cells in the lung earlier 
than  did  tumors  with  the  opposite  relationship  (MC-4  and  MC-5).  Other GERALD R.  IIAYWOOD  AND CHARLES ~'.  I~cKtIANN  1185 
studies on concomitant immunity, showing that an animal can reject an auto- 
graft  from  a  progressively  growing  tumor,  are  consistent  with  these  results 
(28-30). At what point in the course of exposure to a primary tumor metastasis 
develops depends upon a dynamic state between the immunologic capability of 
the host and the antigenic structure of the tumor. 
SUMMARY 
Five methylcholanthrene-induced sarcomas were compared for their capacity 
to (a) absorb monospecific H-2 antisera,  (b) induce tumor-specific immunity in 
syngeneic mice, and (c)  metastasize early to the lungs.  Comparison of the up- 
takes  of monospecific H-2  antisera  by the  five different  tumors  showed that 
each of the tumors had a high, intermediate,  or low surface representation of all 
of the seven specificities tested. No antigenic specificity was completely absent 
from any tumor, and no tumor had an unusually large or small amount of any 
individual specificity. The tumors could be placed in the sequence from one to 
five with  respect  to  their  H-2  antigenicity.  The  same five  tumors  were  also 
ranked with  respect  to their  capacity to induce  a  tumor-specific immune  re- 
sponse in syngeneic mice.  The tumor-specific immunogenicity had an inverse 
relationship  to the H-2 antigenicity in that highly immunogenic tumors were 
those that had quantitatively less H-2 antigen on their surface and vice versa. 
Early metastases  to the lung was associated with low levels of tumor-specific 
immunogenicity and high levels of H-2 antigenicity. 
The authors wish to thank Mrs. Sigrid Nelson and Miss Sharon Kmeger for their excel- 
lent technical assistance. 
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